Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sino-nasal and asthma outcomes with mepolizumab therapy

While mepolizumab improves health-related quality of life and reduces exacerbation frequency in patients with severe eosinophilic asthma (SEA), those with SEA and nasal polyposis have a clinical phenotype that exhibits enhanced benefit with mepolizumab treatment.